Last reviewed · How we verify

NCT05957068: BREXINT

Breast Cancer Exercise Intervention Study

Recruiting now NA Last updated 5 September 2025
What this trial tests

NA trial testing Exercise Programme in Early-stage Breast Cancer in 2,156 participants. Currently enrolling.

Timeline
1 July 2023
Primary endpoint
31 May 2028
31 May 2033

Quick facts

Lead sponsorNational Cancer Centre, Singapore
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment2,156
Start date1 July 2023
Primary completion31 May 2028
Estimated completion31 May 2033
Sites3 locations across Singapore

Drugs / interventions tested

Conditions studied

Sponsor

National Cancer Centre, Singapore

Who can join

Adults 21 to 99, female only, with Early-stage Breast Cancer or Locally Advanced Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a 24-week exercise programme consisting of aerobic exercise and muscle strength training, 3 sessions per week. The first 9 sessions are supervised by physiotherapists in person, followed by 63 sessions monitored remotely (video) or supervised by trainers at ActiveSG (Sport Singapore) gyms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Exercise Programme

Trials testing the same drug.

Other recruiting trials for Early-stage Breast Cancer

Currently open trials in the same condition.

Other National Cancer Centre, Singapore trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05957068.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing